.png)
.png)
Chief Scientific Officer
FleurirABX, LLC
Disclosure(s): FleurirABX, LLC: Board Member, Inventor of company patents, Ownership Interest
John L. Pace, Ph.D. is a microbiologist with 30+ years of anti-infectives R&D experience. Dr. Pace is a named co-inventor on 20 U.S. patents including the FDA approved MRSA antibacterial Vibativ (telavancin). He was the inventor of three vaccine clinical candidates and a technology. He contributed to advancement of 12 candidates into clinical evaluation including the globally approved AvyCaz (ceftazidime/avibactam) in trials spanning 19 countries. Dr. Pace has held leadership positions with both leading pharmaceutical and successful start-up drug-development companies including Stiefel-GlaxoSmithKline, Novexel (acquired by AstraZeneca), Protez (acquired by Novartis), Theravance, Antex Biologics (acquired by Emergent) and Hoffmann-LaRoche (Roche Laboratories). John received the Ph.D. degree in Food Science from the University of Maryland - College Park in 1989, and the B.S. degree in 1982 from Salisbury University. His Ph.D. mentor was Dr. Tuu-jyi Chai, and John postdoced with Dr. Nafsika Georgopapadakou, and Dr. Jorge Galan. John is currently Chief Scientific Officer for FleurirABX, LLC.